Novatrials is now running a clinical study of a potential new treatment aimed at alleviating the symptoms of hyperuricemia. If you suffer with hyperuricemia or high serum uric acid, you …
CONDITION: Blood
GENDER: Both males and females
AGE GROUP:?18?to 75 years
TRIAL STATUS:?Closed: follow-up continuing
Novatrials is seeking volunteers who are overweight to join a clinical study of a potential new weight loss treatment. Under expert medical supervision, participants will explore an innovative new treatment …
CONDITION: Diet and Nutrition
GENDER: Both males and females
AGE GROUP:?18?to 65 years
TRIAL STATUS:?Recruiting
Novatrials is seeking volunteers with vitiligo to join a clinical trial of a potential new treatment. If you are over 18 years of age, either male or female and have …
CONDITION: Inflammatory and Immune System
GENDER:
AGE GROUP:?18?to 75 years
TRIAL STATUS:?Closed: follow-up continuing
Novatrials are seeking volunteers with known heart conditions to join a clinical trial of a potential new treatment. If you are at least 18 years of age, either male or …
CONDITION: Cardiovascular
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Recruiting
Novatrials is seeking volunteers with early symptoms of COVID-19 to join a clinical study of a potential new treatment. This treatment may help improve symptoms, and/or shorten the duration of …
CONDITION: Respiratory
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Closed: follow-up complete
Chronic urticaria is a type of hives lasting six weeks or more without a known cause. Symptoms include red, itchy, raised welts on the skin that can range from small …
CONDITION: Skin
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Closed: follow-up continuing
Participating in a clinical trial is about helping others. You will be helping in the development of new medications which will help improve or even save the lives of people …
CONDITION: Other
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Recruiting
If you are at least 18 years of age, either male or female and: * currently have at least 20% scalp hair loss * you are able to attend appointments …
CONDITION: Skin
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Closed: follow-up continuing
In Australia, 2,000 people a day are treated for skin cancer and 2 in 3 Australians will be diagnosed with skin cancer by the age of 70. Your participation supports research designed …
CONDITION: Cancer
GENDER: Both males and females
AGE GROUP:?18?to 85 years
TRIAL STATUS:?Recruiting
FB102-701: A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Severe to Very Severe Alopecia Areata
CONDITION: Skin
GENDER: All
AGE GROUP:?18?to 75 years
TRIAL STATUS:?Not yet recruiting
A Phase 2, Randomized, Open-label, Active- and Vehicle-controlled Comparator Study to Assess the Safety, Tolerability, and Efficacy of 2.4% Terbinafine Hydrochloride Topical Solution in Patients with Mild to Moderate Onychomycosis …
CONDITION: Skin
GENDER:
AGE GROUP:?18?to 70 years
TRIAL STATUS:?Withdrawn
A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
CONDITION: Skin
GENDER: All
AGE GROUP:?18?to 75 years
TRIAL STATUS:?Active, not recruiting
A Phase 3 Randomized, Active-Controlled, Open-Label Study to Evaluate a Switch to an Oral Weekly Islatravir/ Lenacapavir Regimen in People with HIV-1 Who are Virologically Suppressed on Standard of Care
CONDITION: Other
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)
CONDITION: Other
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP:?18?and above
TRIAL STATUS:?Completed
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
CONDITION: Mental Health
GENDER: All
AGE GROUP:?18?to 65 years
TRIAL STATUS:?Recruiting
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP:?18?and above
TRIAL STATUS:?Completed
CONDITION: Infection
GENDER: Males
AGE GROUP:?18?to 50 years
TRIAL STATUS:?Closed: follow-up complete
This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment …
CONDITION: Infection
GENDER: All
AGE GROUP:?12?and above
TRIAL STATUS:?Completed
A seven year plan of enhanced HCV monitoring, primary care–based workforce development, rapid scale-up of HCV treatment and public health policy action in HIV positive individuals within Australia.
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Completed
This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS-2M) study is designed to demonstrate the non-inferior antiviral activity and safety of CAB LA + RPV LA administered every …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment …
CONDITION: Other
GENDER: All
AGE GROUP:?18?to 65 years
TRIAL STATUS:?Active, not recruiting
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Completed
Australian researchers are testing an investigational drug for Parkinson’s disease symptoms such as motor fluctuations and dyskinesia. This is a 20 week study, in which you will be treated at …
CONDITION: Neurological
GENDER: Both males and females
AGE GROUP:?30?and above
TRIAL STATUS:?Active, not recruiting
This study is being done to see how well a new HIV treatment works compared to current standard treatment. Researchers are testing a single tablet that combines bictegravir (BIC) and …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
This study is for people living with HIV whose treatment is already keeping the virus under control. Researchers are testing whether switching to new medicines, bictegravir and lenacapavir (together in …
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
This study is testing whether people with HIV whose virus is already well controlled can safely switch from their current daily HIV medicines to a new once-a-week pill (islatravir/lenacapavir).
CONDITION: Inflammatory and Immune System
GENDER: All
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
This is a large final-stage (Phase 3) clinical trial testing whether people living with HIV, who already have their virus under control on the standard daily HIV pill (Biktarvy® – …
CONDITION: Inflammatory and Immune System
GENDER: Both males and females
AGE GROUP:?18?and above
TRIAL STATUS:?Active, not recruiting
REZOLV3R is a randomised, double-blind, multi-centre trial treating symptomatic patients with recurrent malignant ascites suitable for paracentesis and a paracentesis-free interval of 28 days or less. The aim of the …
CONDITION: Cancer
GENDER: Both males and females
AGE GROUP:?18?and above
TRIAL STATUS:?Recruiting
Australian researchers are testing a potential new treatment for obesity and weight-related comorbidities in adolescents. This is a 76 week study and may include up to 23 visits. Your adolescent …
CONDITION: Diet and Nutrition
GENDER: All
AGE GROUP:?12?to 17 years
TRIAL STATUS:?Recruiting